Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Adma Biologics (ADMA)

Adma Biologics (ADMA)
17.00 x 2 18.10 x 1
Pre-market by (Cboe BZX)
18.01 -1.44 (-7.40%) 04/04/25 [NASDAQ]
17.00 x 2 18.10 x 1
Pre-market 17.30 -0.71 (-3.94%) 06:19 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
17.65
Day High
19.00
Open 18.44
Previous Close 19.45 19.45
Volume 3,768,700 3,768,700
Avg Vol 3,301,110 3,301,110
Stochastic %K 50.41% 50.41%
Weighted Alpha +89.31 +89.31
5-Day Change -2.25 (-11.11%) -2.25 (-11.11%)
52-Week Range 5.89 - 23.64 5.89 - 23.64
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,257,384
  • Shares Outstanding, K 236,390
  • Annual Sales, $ 426,450 K
  • Annual Income, $ 197,670 K
  • EBIT $ 139 M
  • EBITDA $ 148 M
  • 60-Month Beta 0.53
  • Price/Sales 10.78
  • Price/Cash Flow 35.90
  • Price/Book 13.17

Options Overview Details

View History
  • Implied Volatility 75.99% ( +10.22%)
  • Historical Volatility 62.74%
  • IV Percentile 76%
  • IV Rank 35.67%
  • IV High 171.68% on 04/05/24
  • IV Low 22.93% on 05/16/24
  • Put/Call Vol Ratio 0.25
  • Today's Volume 2,294
  • Volume Avg (30-Day) 4,219
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 53,107
  • Open Int (30-Day) 52,087

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.16
  • Number of Estimates 1
  • High Estimate 0.16
  • Low Estimate 0.16
  • Prior Year 0.08
  • Growth Rate Est. (year over year) +100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.88 +13.41%
on 03/07/25
Period Open: 17.01
20.70 -13.00%
on 03/25/25
+1.00 (+5.88%)
since 03/04/25
3-Month
13.50 +33.41%
on 03/04/25
Period Open: 18.44
20.70 -13.00%
on 03/25/25
-0.43 (-2.33%)
since 01/03/25
52-Week
5.89 +205.51%
on 04/10/24
Period Open: 6.28
23.64 -23.82%
on 11/11/24
+11.73 (+186.78%)
since 04/04/24

Most Recent Stories

More News
ADMA Biologics Statement on Tariffs

ADMA : 18.01 (-7.40%)
Ensign Group Invests in Growth With New Facility Acquisitions

The Ensign Group, Inc. ENSG recently announced a series of strategic acquisitions across Washington and California. These acquisitions, effective April 1, 2025, underscore the company’s commitment to...

OPCH : 33.54 (-4.01%)
ADMA : 18.01 (-7.40%)
ENSG : 129.33 (-3.41%)
BVS : 8.33 (-8.96%)
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook

CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024.

IJR : 94.63 (-4.32%)
ADMA : 18.01 (-7.40%)
VTI : 248.47 (-5.87%)
XBI : 73.66 (-5.73%)
Adma Biologics: Q4 Earnings Snapshot

Adma Biologics: Q4 Earnings Snapshot

ADMA : 18.01 (-7.40%)
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

ADMA : 18.01 (-7.40%)
ADMA Biologics to Participate in the Raymond James Institutional Investor Conference

ADMA : 18.01 (-7.40%)
ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

ADMA : 18.01 (-7.40%)
ADMA Biologics Gears Up to Report Q4 Earnings: What's in the Cards?

We expect investors to focus on the sales performance of ADMA Biologics’ ADMA portfolio of marketed products and other pipeline updates when it reports fourth-quarter 2024 results.See the Zacks Earnings...

VKTX : 22.62 (-6.61%)
MIRM : 42.03 (-2.78%)
ADMA : 18.01 (-7.40%)
PCRX : 23.10 (-4.90%)
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.

GRAL : 22.25 (-10.57%)
ADMA : 18.01 (-7.40%)
EXEL : 34.57 (-5.75%)
GLYC : 0.1800 (-2.76%)
MBRX : 0.8201 (-5.59%)
There May Still Be Time to Get in on These 3 Trending Biotechs

Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025.

AVDL : 6.80 (-5.56%)
SANA : 1.4800 (+8.03%)
IBB : 117.16 (-5.36%)
ADMA : 18.01 (-7.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 20.14
2nd Resistance Point 19.57
1st Resistance Point 18.79
Last Price 18.01
1st Support Level 17.44
2nd Support Level 16.87
3rd Support Level 16.09

See More

52-Week High 23.64
Last Price 18.01
Fibonacci 61.8% 16.86
Fibonacci 50% 14.77
Fibonacci 38.2% 12.67
52-Week Low 5.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades